Report Description Table of Contents Methodology Segmentation Injectable Drug Delivery Market – Industry Report & Statistics (Sales Volume, ASP & Number of Procedures by Product Type, Devices & Application) Market Size & Growth Outlook The global injectable drug delivery market was valued at USD 615.87 billion in 2021 and is projected to reach USD 1,677.91 billion by 2030, expanding at a CAGR of 11.78% Growth is primarily driven by the increasing prevalence of chronic diseases, the rising incidence of needle injuries, and the widespread use of injections across therapeutic areas. Key Industry Drivers Rising Burden of Chronic Diseases According to the National Health Council, chronic diseases affect 133 million people in the U.S., representing >40% of the population. By 2020, this number was projected to rise to 157 million, with 81 million individuals suffering from multiple conditions. The WHO reports that non-communicable diseases (NCDs) cause 41 million deaths annually, equivalent to 71% of all global deaths. Of these, 15 million deaths occur prematurely (ages 30–69), with 85% of premature deaths in low- and middle-income countries. Breakdown of NCD-related deaths: Cardiovascular diseases (CVDs): 17.9 million annually Cancers: 9.3 million Respiratory diseases: 4.1 million Diabetes: 1.5 million The rising prevalence of these conditions is a key driver of injectable drug delivery demand. Technological Advancements & Biologics Rapid innovation in injectable formulations and devices is fueling adoption. The increasing use of biologics has further accelerated demand for injectable delivery systems. According to the CDC, U.S. healthcare workers experience 600,000–1 million needlestick and sharp injuries annually, highlighting the need for safer, more advanced injection technologies. Expanding Product Portfolio The market is also driven by rising demand for: In situ forming implants Drug implants Polymer-based microspheres Oil-based injectable solutions Injectable suspensions Sustained-release injectable drug delivery systems These innovations are expanding therapeutic applications and improving patient compliance. Market Restraints Risk of Blood-Borne Diseases Needle sharing and improper injection practices increase the risk of Hepatitis C, HIV/AIDS, and abscessed infections. Lack of aseptic technique and poor hygiene during administration remain significant barriers to safe adoption. Product Recalls Product recalls impose substantial financial losses on manufacturers due to retrieval, replacement, and remediation costs. Recalls negatively impact company revenues, market share, and brand reputation, thereby restraining overall market growth. Market Opportunities Government Funding for Contraceptive Injectables Increased government investment in contraceptive injectables such as Depot Medroxyprogesterone Acetate (DMPA) and Norethisterone Enanthate (NET-EN) is expected to create significant growth opportunities. These initiatives are anticipated to accelerate adoption rates and expand access in both developed and emerging markets. Segmentation Analysis & Insights By Device Type Conventional Injectables dominated the market in 2020, supported by: Rising incidence of infectious diseases Increased hospital admissions and surgical procedures Large-scale immunization programs This segment continues to grow at a steady CAGR. By Product Injectable Sterile Products accounted for 67.38% of market share in 2020. Key advantages include: High storage capacity Quality assurance Pathogen-free formulations, reducing infection risks These products are widely preferred in hospitals for treating complex diseases. By Application The Hormonal Disorders segment led the market in 2020, driven by: Eating disorders Thyroid dysfunction Stress-related conditions Low libido and irregular menstrual cycles Unexplained weight gain and mood swings By End-User Hospitals dominated with 62.17% share in 2020. Growth is supported by: Increased government funding for healthcare Longer patient stays for chronic and acute conditions High procedural volumes requiring injectable therapies By Region North America: Largest market in 2020, valued at USD 194.89 billion, with a CAGR of 12.87%. Growth driven by adoption of injectable technologies for diabetes, cancer, and autoimmune disorders. According to the ADA, in 2018, 30.3 million Americans were diagnosed with diabetes. Asia Pacific: Fastest-growing region in 2020, supported by: Expanding patient pool Growth in healthcare infrastructure Shift from conventional injectables to ready-to-use formulations Competitive Landscape Analysis A 360-degree competitive assessment is essential to evaluate the leading players in the global injectable drug delivery market. Competitive benchmarking is based on: Total revenue generation Company strengths and weaknesses Global presence and market initiatives R&D investments and innovation pipelines Production capacity and facilities Financial performance and market potential This competitive landscape highlights the balance between established multinational corporations and emerging regional players, with innovation, safety, and scalability serving as the primary differentiators. Strategic Outlook The injectable drug delivery market is positioned for sustained double-digit growth, supported by: Rising chronic disease prevalence Technological advancements in injectables and biologics Government funding for contraceptive injectables Expanding hospital and healthcare infrastructure However, risks of blood-borne disease transmission, product recalls, and safety concerns remain critical challenges that must be addressed to ensure long-term market stability. Global Injectable Drug Delivery Market Competitive Landscape Analysis A 360-degree competitive landscape is crucial in figuring out the main competitors that are prevailing in the global market environment. The comparison is performed based on the total revenue generated, company strengths and flaws, company overview, global presence, market initiatives, market potential, company financials, investments in the field of R&D, production capability, production sites & facilities, etc. Becton, Dickinson, and Company Pfizer Inc. Teva Pharmaceuticals Industries Ltd. Eli Lilly and Company Baxter International, Inc. Schott AG Gerresheimer Ypsomed B. Braun Melsungen Report Attribute Details Forecast Period 2021 - 2030 The market size value in 2021 USD 615.87 Billion The revenue forecast in 2030 USD 1677.91 Billion Growth rate CAGR of approximately 11.78% The base year for estimation 2021 Historical data 2017 – 2020 Unit USD Billion, CAGR (2021 - 2030) Segmentation By Device Type, By Products, By Applications, By End-User, By Region. By Device Type Convention Injectables, Pre-filled syringes, Auto-Injectors, Pen-Injectables, Wearable By Products Freeze Dried Products, Injectable Sterile Products. By Applications Hormonal Disorders, Auto-Immune Diseases, Oncology, Orphan/Rare Diseases, Others. By End-User Hospitals, Home Care Settings, Others. By Region North America, Europe, Asia Pacific, Rest of Asia-Pacific. Country Scope United States of America, United Kingdom, Italy, Germany, France, Spain, Canada, China, India, Japan, Brazil, Argentina, Mexico, South Africa, Saudi Arabia, etc. Company Usability Profiles Becton, Dickinson, and Company, Pfizer Inc., Teva Pharmaceuticals Industries Ltd, Eli Lilly and Company, Baxter International, Inc, Schott AG, Gerresheimer, Ypsomed. B. Braun Melsungen. 1. Introduction 1.1. Study Objective 1.2. Market Definition 1.3. Study Scope 1.3.1. Markets Covered 1.3.2. Geographic Scope 1.3.3. Years Considered 1.3.4. Stakeholders 2. Research Methodology 2.1. Data Procurement 2.2. Paid Database 2.2.1. Secondary Data 2.2.1.1. Key Secondary sources 2.2.2. Primary Data 2.2.2.1 Primary sources 2.2.2.2. Key industry insights 2.2.2.3. Primary interviews with experts 2.2.2.4. Key primary respondent list 2.3. Market Size Estimation 2.4. Bottom-Up and Top-Down Approaches 2.4.1. Bottom-Up Approach 2.4.1.1. Approach for arriving at market size by bottom-up analysis 2.4.2. Top-Down Approach 2.4.2.1. Approach for Capturing Market Size by Top-Down Analysis 2.5. Market Breakdown and Data Triangulation 2.6. Research Methodology 2.7. Risk Assessment 3. Executive Summary 3.1 Market: Post-Covid-19 3.1.1 Actual Scenario 3.1.2 Pessimistic Scenario 3.1.3 Optimistic Scenario 3.1.4 Market Summary 4. Industry Outlook 4.1 Market Snapshot 4.2 Global Injectable Drug Delivery Market 4.2.1 Global Market, 2021 – 2030 (USD Million) 4.3 Regional Business Analysis 4.3.1 Global Market, by region, 2021 - 2030 (USD Million) 4.4 By Product Business Analysis 4.4.1 Global Market, By Product, 2021 - 2030 (USD Million) 4.5 By Device Type Business Analysis 4.5.1 Global Market, By Device Type, 2021 - 2030 (USD Million) 4.6 Application Business Analysis 4.6.1 Global Market, By Application, 2021 - 2030 (USD Million) 4.6 End-User Business Analysis 4.6.1 Global Market, By End-User, 2021 - 2030 (USD Million) 4.7 Value Chain Analysis 4.8 Market Variable Analysis 4.8.1 Market Drivers Analysis 4.8.2 Market Restraints Analysis 4.9 Business Environment Analysis Tool 4.9.1 Market PEST analysis 4.9.2 Market Porter’s analysis 4.10 Penetration & Growth Prospect Mapping 5. Market Dynamics 5.1. Introduction 5.2. Market Dynamics 5.2.1. Drivers 5.2.2. Restraints 5.2.3. Opportunities 5.2.4. Challenges 5.3. Impact of Covid-19 On Market 5.4. Value Chain Analysis 5.5. Ecosystem 5.6. Patent Analysis 5.7. Trade Analysis 5.8. Tariff Analysis 5.9. Case Study Analysis 5.10. Porter’s Five Forces Analysis 5.10.1 Threat of New Entrants 5.10.2 Threat of Substitutes 5.10.3 Bargaining Power of Buyers 5.10.4 Bargaining Power of Suppliers 5.10.5 Degree of Competition 5.11. End-User Analysis 5.11.1. Trends in End-User (2014-2020) 5.11.2. Trends in End-User (2021-2028) 5.12. Pricing Analysis 5.12.1. Average Price Trend Analysis (By region, By Countries) 6. Competitive & Vendor Landscape 6.1. Company Market Share Analysis 6.2. Manufacturers Injectable Drug Delivery Manufacturing Sites, Area Served, Product Product 6.3. Market Competitive Situation and Trends 6.4. Manufacturers Mergers & Acquisitions, Expansion Plans 7. Global Market: By Product Segment Analysis 7.1. Introduction 7.2. Sales Volume & Revenue Analysis (2021-2030) 7.3. Freeze Dried Products 7.3.1. Freeze Dried Products market, 2021 - 2030 (USD Million) 7.4. Injectable Sterile Products 7.4.1. Injectable Sterile Products market, 2021 - 2030 (USD Million) 8. Global Market: By Device Type Segment Analysis 8.1. Introduction 8.2. Sales Volume & Revenue Analysis (2021-2030) 8.3. Convention Injectables 8.3.1. Convention Injectables market, 2021 - 2030 (USD Million) 8.4. Pre-filled syringes 8.4.1. Pre-filled syringes market, 2021 - 2030 (USD Million) 8.5. Auto-Injectors 8.5.1. Auto-Injectors market, 2021 - 2030 (USD Million) 8.6. Pen-Injectables 8.6.1. Pen-Injectables market, 2021 - 2030 (USD Million) 8.7. Wearable 8.7.1. Wearable market, 2021 - 2030 (USD Million) 9. Global Market: By Application Segment Analysis 9.1. Introduction 9.2. Sales Volume & Revenue Analysis (2021-2030) 9.3. Hormonal Disorders 9.3.1. Hormonal Disorders market, 2021 - 2030 (USD Million) 9.4. Auto-Immune Diseases 9.4.1. Auto-Immune Diseases market, 2021 - 2030 (USD Million) 9.5. Oncology 9.5.1. Oncology market, 2021 - 2030 (USD Million) 9.6. Orphan/Rare Diseases 9.6.1. Orphan/Rare Diseases market, 2021 - 2030 (USD Million) 9.7. Others 9.7.1. Others market, 2021 - 2030 (USD Million) 10. Global Market: By End-User Segment Analysis 10.1. Introduction 10.2. Sales Volume & Revenue Analysis (2021-2030) 10.3. Hospitals 10.3.1. Hospitals market, 2021 - 2030 (USD Million) 10.4. Home Care Settings 10.4.1. Home Care Settings market, 2021 - 2030 (USD Million) 10.5. Others 10.5.1. Others market, 2021 - 2030 (USD Million) 11. Global Market: Regional Outlook 11.1 North America 11.1.1. North America Market, by By Product, 2021 - 2030 (USD Million) 11.1.2. North America Market, by By Device Type, 2021 - 2030 (USD Million) 11.1.3. North America Market, by End-User, 2021 - 2030 (USD Million) 11.1.4. North America Market, by Country, 2021 - 2030 (USD Million) 11.1.4.1. U.S. 11.1.4.1.1. U.S. Market, by By Product, 2021 - 2030 (USD Million) 11.1.4.1.2. U.S. Market, by By Device Type, 2021 - 2030 (USD Million) 11.1.4.1.3. U.S. Market, by End-User, 2021 - 2030 (USD Million) 11.1.4.2. Canada 11.1.4.2.1. Canada Market, by By Product, 2021 - 2030 (USD Million) 11.1.4.2.2. Canada Market, by By Device Type, 2021 - 2030 (USD Million) 11.1.4.2.3. Canada Market, by End-User, 2021 - 2030 (USD Million) 11.2. Europe 11.2.1. Europe Market, by By Product, 2021 - 2030 (USD Million) 11.2.2. Europe Market, by By Device Type, 2021 - 2030 (USD Million) 11.2.3. Europe Market, by End-User, 2021 - 2030 (USD Million) 11.2.4. Europe Market, by country, 2021 - 2030 (USD Million) 11.2.4.1 U.K. 11.2.4.1.1. U.K. Market, by By Product, 2021 - 2030 (USD Million) 11.2.4.1.2. U.K. Market, by By Device Type, 2021 - 2030 (USD Million) 11.2.4.1.3. U.K. Market, by End-User, 2021 - 2030 (USD Million) 11.2.4.2. Germany 11.2.4.2.1. Germany Market, by By Product, 2021 - 2030 (USD Million) 11.2.4.2.2. Germany Market, by By Device Type, 2021 - 2030 (USD Million) 11.2.4.2.3. Germany Market, by End-User, 2021 - 2030 (USD Million) 11.2.4.3. France 11.2.4.3.1. France Market, by By Product, 2021 - 2030 (USD Million) 11.2.4.3.2. France Market, by By Device Type, 2021 - 2030 (USD Million) 11.2.4.3.3. France Market, by End-User, 2021 - 2030 (USD Million) 11.2.4.4. Rest of Europe 11.2.4.4.1. Rest of Europe Market, by By Product, 2021 - 2030 (USD Million) 11.2.4.4.2. Rest of Europe Market, by By Device Type, 2021 - 2030 (USD Million) 11.2.4.4.3. Rest of Europe Market, by End-User, 2021 - 2030 (USD Million) 11.3. Asia Pacific 11.3.1. Asia Pacific Market, by By Product, 2021 - 2030 (USD Million) 11.3.2. Asia Pacific Market, by By Device Type, 2021 - 2030 (USD Million) 11.3.3. Asia Pacific Market, by End-User, 2021 - 2030 (USD Million) 11.3.4. Asia Pacific Market, by country, 2021 - 2030 (USD Million) 11.3.4.1. China 11.3.4.1.1. China Market, by By Product, 2021 - 2030 (USD Million) 11.3.4.1.2. China Market, by By Device Type, 2021 - 2030 (USD Million) 11.3.4.1.3. China Market, by End-User, 2021 - 2030 (USD Million) 11.3.4.2. India 11.3.4.2.1. India Market, by By Product, 2021 - 2030 (USD Million) 11.3.4.2.2. India Market, by By Device Type, 2021 - 2030 (USD Million) 11.3.4.2.3. India Market, by End-User, 2021 - 2030 (USD Million) 11.3.4.3. Japan 11.3.4.3.1. Japan Market, by By Product, 2021 - 2030 (USD Million) 11.3.4.3.2. Japan Market, by By Device Type, 2021 - 2030 (USD Million) 11.3.4.3.3. Japan Market, by End-User, 2021 - 2030 (USD Million) 11.3.4.4. South Korea 11.3.4.4.1. South Korea Market, by By Product, 2021 - 2030 (USD Million) 11.3.4.4.2. South Korea Market, by By Device Type, 2021 - 2030 (USD Million) 11.3.4.4.3. South Korea Market, by End-User, 2021 - 2030 (USD Million) 11.3.4.5. Rest of ASIA PACIFIC 11.3.4.5.1. Rest of ASIA PACIFIC Market, by By Product, 2021 - 2030 (USD Million) 11.3.4.5.2. Rest of ASIA PACIFIC Market, by By Device Type, 2021 - 2030 (USD Million) 11.3.4.5.3. Rest of ASIA PACIFIC Market, by End-User, 2021 - 2030 (USD Million) 11.4. Latin America 11.4.1. Latin America Market, by By Product, 2021 - 2030 (USD Million) 11.4.2. Latin America Market, by By Device Type, 2021 - 2030 (USD Million) 11.4.3. Latin America Market, by End-User, 2021 - 2030 (USD Million) 11.4.4. Latin America Market, by country, 2021 - 2030 (USD Million) 11.4.4.1. Brazil 11.4.4.1.1. Brazil Market, by By Product, 2021 - 2030 (USD Million) 11.4.4.1.2. Brazil Market, by By Device Type, 2021 - 2030 (USD Million) 11.4.4.1.3. Brazil Market, by End-User, 2021 - 2030 (USD Million) 11.4.4.2. Mexico 11.4.4.2.1. Mexico Market, by By Product, 2021 - 2030 (USD Million) 11.4.4.2.2. Mexico Market, by By Device Type, 2021 - 2030 (USD Million) 11.4.4.2.3. Mexico Market, by End-User, 2021 - 2030 (USD Million) 11.4.4.3. Rest of the Latin America 11.4.4.3.1. Rest of the Latin America Market, by By Product, 2021 - 2030 (USD Million) 11.4.4.3.2. Rest of the Latin America Market, by By Device Type, 2021 - 2030 (USD Million) 11.4.4.3.3. Rest of the Latin America Market, by End-User, 2021 - 2030 (USD Million) 11.5. MEA 11.5.1. MEA Market, by By Product, 2021 - 2030 (USD Million) 11.5.2. MEA Market, by By Device Type, 2021 - 2030 (USD Million) 11.5.3. MEA Market, by End-User, 2021 - 2030 (USD Million) 11.5.4. MEA Market, by Region, 2021 - 2030 (USD Million) 12. Competitive Landscape 12.1 Becton, Dickinson, and Company 12.1.1. Company overview 12.1.2. Financial performance 12.1.3. Product Portfolio Analysis 12.1.4. Business Strategy & Recent Development 12.2. Pfizer Inc. 12.2.1. Company overview 12.2.2. Financial performance 12.2.3. Product Portfolio Analysis 12.2.4. Business Strategy & Recent Development 12.3. Teva Pharmaceuticals Industries Ltd. 12.3.1. Company overview 12.3.2. Financial performance 12.3.3. Product Portfolio Analysis 12.3.4. Business Strategy & Recent Development 12.4. Eli Lilly and Company 12.4.1. Company overview 12.4.2. Financial performance 12.4.3. Product Portfolio Analysis 12.4.4. Business Strategy & Recent Development 12.5. Baxter International, Inc. 12.5.1. Company overview 12.5.2. Financial performance 12.5.3. Product Portfolio Analysis 12.5.4. Business Strategy & Recent Development 12.6. Schott AG 12.6.1. Company overview 12.6.2. Financial performance 12.6.3. Product Portfolio Analysis 12.6.4. Business Strategy & Recent Development 12.7. Gerresheimer 12.7.1. Company overview 12.7.2. Financial performance 12.7.3. Product Portfolio Analysis 12.7.4. Business Strategy & Recent Development 12.8. Ypsomed 12.8.1. Company overview 12.8.2. Financial performance 12.8.3. Product Portfolio Analysis 12.8.4. Business Strategy & Recent Development 12.9. B. Braun Melsungen 12.9.1. Company overview 12.9.2. Financial performance 12.9.3. Product Portfolio Analysis 12.9.4. Business Strategy & Recent Development . .